[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-tumors":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,37,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100580668","bronchoscopic-lung-ablation-of-small-thoracic-tumors-the-blastt-registry-100580668",false,"NCT06840288","Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry","Inclusion Criteria:\n\nPatients with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy.\n\nExclusion Criteria:\n\nPatients with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).","ALL","18 Years",{"count":18,"type":19},250,"ESTIMATED","OBSERVATIONAL","To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.",[23],"Thoracic Tumors","RECRUITING","2026-06-10",{"date":27,"type":28},"2026-06-12","ACTUAL",{"date":30,"type":28},"2025-02-19",{"date":32,"type":19},"2036-12-31",{"name":34,"class":35},"M.D. Anderson Cancer Center","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":44,"targetDuration":46,"studyType":20,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":58},"100281284","thoracic-tumours-register-100281284","NCT02941458","Thoracic Tumours Register","RTT","Inclusion Criteria:\n\n* Patients with thoracic disease, treated with an active treatment or not treated (only palliative care)\n\nExclusion Criteria:\n\n* Patients with other type of tumours",{"count":45,"type":19},10000,"10 Years","Observational, multicenter study in patients with lung cancer and other thoracic tumors.\n\nThe GECP, in its commitment to improve the treatment and prognosis of patients with lung cancer and other thoracic tumors, has marked the individualization of treatment according to the expression of markers predictive of response to chemotherapeutic agents and molecular inhibitors of cell proliferation as one of its primary objectives. This could significantly improve the prognosis of patients with lung cancer, and will lead to a radical change in routine clinical practice. The aim of the register is to explore all data available of all patients treated because of thoracic tumours.",[23],"2026-04-22",{"date":51,"type":28},"2026-04-23",{"date":53,"type":28},"2016-07-21",{"date":55,"type":19},"2031-12-30",{"name":57,"class":35},"Spanish Lung Cancer Group",79,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":36},"100604810","community-exercise-treating-effect-on-cardiopulmonary-disease-patients-100604810","NCT07154355","Community Exercise Treating Effect on Cardiopulmonary Disease Patients","Clinical Study Protocol on the Impact of Community-Based Exercise Training on the Exercise Capacity of Patients With Reduced Cardiovascular and Pulmonary Function","Inclusion Criteria:\n\n1. Patients aged 18 to 85 with abnormal pulmonary or cardiovascular function.\n2. Individuals who have completed a medical screening form to confirm they are free from illnesses and prescription medications that could impair their ability to complete the required testing and fitness training.\n3. Participants who did not engage in structured, systematic moderate-to-intense strength or endurance training during the study period (specifically, not within the previous year).\n4. At the onset of the trial, participants were physically active but had never participated in formal exercise more than twice a week.\n\nExclusion Criteria:\n\n1. Patients with neuromuscular or skeletal disorders, or systemic diseases such as diabetes, cancer, or heart disease.\n2. Individuals using medications known to affect health or the interpretation of study results.\n3. Participants who have engaged in organized, systematic endurance or strength training of moderate to high intensity within the past year.\n4. Patients who decline to participate in the study.\n5. Other medical conditions or states that render exercise training inappropriate.","85 Years",{"count":68,"type":19},200,"INTERVENTIONAL",[71],"NA","The goal of this clinical trial is to learn if community-based exercise training can benefit patients aged 18 to 85 with diminished cardiovascular and pulmonary function. The main aim of this study is:\n\n• Establish a community or home-based fitness training program for patients with cardiopulmonary insufficiency to improve adherence, safety, and efficacy while alleviating the burden on both patients and society.\n\nResearchers will compare community-based exercise training to non-exercise training to see if community-based exercise training works to improve cardiovascular and pulmonary function.\n\nParticipants will:\n\n* Engage in community or home exercise training for 40-60 minutes, five times weekly, during a duration of eight weeks. Exercise modalities are primarily determined by the patients' individual preferences and habits, such as brisk walking, running, swimming, cycling, and hiking.\n* Adjust the exercise intensity according to their cardiopulmonary exercise test and the person's perceived exertion level.\n* Utilize fitness bracelets or watches to document statistics during workouts and submit them to the experimenter weekly, covering the five days of exercise within that week.\n* refrain from making any dietary modifications throughout the trial.",[74,75,76,77,78,79,23,80],"Coronary Heart Disease (CHD)","Heart Failure","Cardiomyopathy","COPD","Bronchial Asthma","Respiratory Failure","Cardiopulmonary Diseases","2025-08-26",{"date":83,"type":28},"2025-09-04",{"date":85,"type":28},"2025-01-30",{"date":87,"type":19},"2030-12",{"name":89,"class":35},"Guangdong Provincial People's Hospital"]